IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.701
NA - Nord America 8.730
AS - Asia 5.107
SA - Sud America 669
AF - Africa 178
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 21
Totale 26.439
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.334
IT - Italia 3.377
RU - Federazione Russa 2.988
FI - Finlandia 1.641
CN - Cina 1.580
SG - Singapore 1.399
IE - Irlanda 1.112
GB - Regno Unito 579
VN - Vietnam 547
BR - Brasile 522
UA - Ucraina 429
DE - Germania 425
HK - Hong Kong 412
FR - Francia 317
CA - Canada 297
SE - Svezia 247
TR - Turchia 226
IN - India 167
KR - Corea 156
NL - Olanda 135
BD - Bangladesh 115
ZA - Sudafrica 94
ID - Indonesia 77
MX - Messico 74
IL - Israele 72
PL - Polonia 68
BG - Bulgaria 58
CZ - Repubblica Ceca 54
KZ - Kazakistan 54
IQ - Iraq 46
ES - Italia 45
AR - Argentina 44
JP - Giappone 43
BE - Belgio 39
PK - Pakistan 36
AT - Austria 28
AU - Australia 28
EC - Ecuador 26
IR - Iran 25
RO - Romania 24
VE - Venezuela 23
MA - Marocco 21
AE - Emirati Arabi Uniti 20
PT - Portogallo 20
CH - Svizzera 18
LT - Lituania 18
EU - Europa 17
PH - Filippine 16
CL - Cile 15
CO - Colombia 15
TN - Tunisia 14
UZ - Uzbekistan 14
DK - Danimarca 13
AZ - Azerbaigian 12
EG - Egitto 12
MY - Malesia 12
SA - Arabia Saudita 11
KE - Kenya 10
JO - Giordania 9
LV - Lettonia 9
PE - Perù 9
GR - Grecia 8
HU - Ungheria 8
NO - Norvegia 8
TH - Thailandia 7
KG - Kirghizistan 6
OM - Oman 6
SN - Senegal 6
UY - Uruguay 6
DZ - Algeria 5
LA - Repubblica Popolare Democratica del Laos 5
NG - Nigeria 5
PY - Paraguay 5
BO - Bolivia 4
BY - Bielorussia 4
ET - Etiopia 4
JM - Giamaica 4
LU - Lussemburgo 4
MD - Moldavia 4
NP - Nepal 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AD - Andorra 3
AL - Albania 3
AM - Armenia 3
BH - Bahrain 3
CR - Costa Rica 3
GE - Georgia 3
HN - Honduras 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EE - Estonia 2
LB - Libano 2
RS - Serbia 2
Totale 26.409
Salva come PNG Salva come JPEG
Città #
Helsinki 1.533
Ashburn 1.347
Dublin 1.108
San Jose 1.090
Milan 719
Chandler 673
Singapore 673
Moscow 611
Hefei 553
Dallas 469
Hong Kong 405
Beijing 336
Jacksonville 335
New York 281
Ann Arbor 258
Rome 253
Southend 215
Toronto 202
Los Angeles 200
The Dalles 175
Edison 166
Redmond 149
Seoul 149
Dearborn 146
Ho Chi Minh City 141
Lauterbourg 137
Dong Ket 130
Houston 130
Wilmington 116
Hanoi 105
Boston 101
Council Bluffs 101
Lawrence 97
Modena 97
Boardman 92
Johannesburg 84
Munich 80
Naples 78
Buffalo 77
Izmir 71
Frankfurt am Main 68
Jakarta 68
Tel Aviv 66
São Paulo 65
Bologna 53
Almaty 50
Orem 50
Redwood City 50
Seattle 50
Mountain View 48
Palombara Sabina 47
Warsaw 47
Lappeenranta 46
Chennai 44
Santa Clara 40
Woodbridge 40
Tokyo 38
Fairfield 36
Montreal 36
Florence 35
Genoa 35
Turin 35
Bari 32
Mexico City 32
Atlanta 31
Brussels 31
Poplar 31
London 30
Nuremberg 30
Denver 29
San Francisco 29
Stockholm 29
Brooklyn 28
Fremont 27
Washington 27
Amsterdam 24
Chicago 24
Catania 23
Ottawa 23
Da Nang 21
Belo Horizonte 20
Brno 20
Guangzhou 20
Ankara 18
Assago 18
Verona 17
Bucharest 16
Düsseldorf 16
Kunming 16
Nanjing 16
Rio de Janeiro 16
Brescia 15
Falkenstein 15
Vienna 15
West Jordan 15
Palermo 14
Phoenix 14
Tashkent 14
Trieste 14
Haiphong 13
Totale 15.553
Salva come PNG Salva come JPEG
Nome #
Esiti di salute e performance del Servizio Sanitario Nazionale 469
EQ-5D-5L population norms for Italy 467
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 434
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 431
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 389
I dispositivi medici in Italia: un settore, tanti mercati 340
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 324
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 314
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 309
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 287
Gli esiti di salute del Servizio Sanitario Nazionale 286
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 285
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 276
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 274
An economic perspective on urinary tract infection: the "costs of resignation" 271
La dimensione del settore dei dispositivi medici 265
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 250
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 249
Gli esiti di salute del Servizio Sanitario Nazionale 248
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 245
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 245
Surrogate endpoints: a key concept in clinical epidemiology 242
Current and Future Trends in the HTA of Medical Devices 242
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 242
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 240
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 230
Distinguishing features in the assessment of mHealth apps 221
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy 219
Broadening the concept of value: a scoping review on the option value of medical technologies 219
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 218
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 217
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 214
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 214
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 214
Coverage with evidence development for medical devices in Europe: can practice meet theory? 210
A more evidence based approach to the use of surrogate end points in policy making 206
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 206
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 205
Measuring value in health care: a comparative analysis of value-based frameworks 201
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 200
European diabetes research and its funding, 2002–2013 198
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 198
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 196
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 195
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 195
Esiti di salute e performance del Servizio Sanitario Nazionale 194
Esiti di salute e performance del Servizio Sanitario Nazionale 194
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 194
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 191
Esiti di salute e performance del Servizio Sanitario Nazionale 189
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 187
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 187
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 186
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 185
Strumenti a supporto del processo decisionale condiviso in oncologia 184
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 182
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project 177
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 177
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 177
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 174
Comparing drug and non-drug technologies in comparative effectiveness research 173
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 172
The Coronavirus pandemic and inequality in Italy 172
Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review 171
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 169
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 168
Core outcome set in surgical oncology: why, what and how to measure 168
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need-driven classification 166
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 166
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 166
Introduction to economic evaluation and health technology assessment 165
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 165
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 163
Esiti di salute e performance del Servizio Sanitario Nazionale 163
Time to review the role of surrogate end points in health policy: state of the art and the way forward 163
A call for better reporting of trials using surrogate primary endpoints 160
Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments 160
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials 160
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 157
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 153
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 153
Surrogate endpoints in trials-a call for better reporting 152
The development of an Archive of Patient-Reported Outcome Measures (PROMs) in Oncology: The Italian PRO4All Project 150
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 150
Machine learning-assisted health economics and policy reviews: a comparative assessment 147
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 147
The impacts of diabetes research from 31 European Countries in 2002 to 2013 147
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 147
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy 146
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 146
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 146
The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy 145
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 144
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 143
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 142
Response to COVID-19: was Italy (un)prepared? 141
Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting 140
The rise of rules: will the new regulation of medical devices make us safer? 140
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study 139
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework 139
Totale 20.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021371 0 0 0 0 0 0 0 0 0 0 116 255
2021/20221.500 107 220 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/202612.565 758 986 365 850 1.023 463 1.387 1.224 3.492 1.542 475 0
Totale 26.930